Study guide

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control

Key Takeaways Explain This Topic AI

Under the 2026 AHA/ASA acute ischemic stroke guideline, IV thrombolysis with alteplase (0.9 mg/kg, max 90 mg; 10% bolus, rest over 60 min) or tenecteplase (0.25 mg/kg single bolus, max 25 mg) is standard within 4.5 hours of last known well for disabling deficits.

Blood pressure must be strictly maintained below 185/110 mmHg prior to thrombolytic initiation and below 180/105 mmHg for at least 24 hours post-thrombolysis, using IV titratable infusions of nicardipine, clevidipine, or intermittent labetalol boluses.

Classic exclusions include intracranial hemorrhage on CT, ischemic stroke or severe head trauma within 3 months, intra-axial neoplasm, GI bleeding within 21 days, platelets below 100,000/mcL, INR above 1.7, recent full-dose LMWH or DOAC, and BP that cannot be brought below 185/110 mmHg.

Symptomatic post-thrombolytic intracranial hemorrhage mandates immediate infusion cessation, emergent non-contrast CT, and reversal with 10 units of cryoprecipitate (target fibrinogen >150 mg/dL) plus IV tranexamic acid 1000 mg; orolingual angioedema is managed with antihistamines, corticosteroids, and icatibant.

The 2026 guideline extends thrombolysis to selected patients with salvageable tissue on advanced imaging (wake-up or 4.5–9 hours from last known well, and large-vessel occlusion up to 24 hours when thrombectomy is unavailable) and recommends dual antiplatelet therapy rather than thrombolysis for non-disabling minor stroke.

Last updated: October 2026

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control

Note

Independent BCEMP study resource provided by ExamFinch. Content is organized around neurocritical care and emergency pharmacotherapy principles.

Acute ischemic stroke (AIS) represents a hyperacute medical emergency in which rapid diagnostic assessment and prompt pharmacotherapeutic intervention directly dictate long-term neurological recovery. Under the pathophysiologic paradigm that "time is brain," an estimated 1.9 million neurons, 14 billion synapses, and 7.5 miles of myelinated axons are destroyed every minute an ischemic stroke remains untreated. The primary pharmacotherapeutic objective in the emergency department (ED) is the rapid restoration of cerebral blood flow to the salvageable ischemic penumbra before irreversible infarction ensues, while concurrently controlling blood pressure to prevent secondary hemorrhagic transformation.

Thrombolytic Pharmacotherapy: Alteplase vs. Tenecteplase

Recombinant tissue plasminogen activators (tPA) promote fibrinolysis by selectively binding to fibrin on the thrombus surface and converting clot-bound plasminogen into active plasmin. Plasmin cleaves fibrin polymers into soluble fibrin degradation products, dissolving the occlusive intravascular thrombus.

Alteplase (rt-PA)

Alteplase remains the historically established standard of care for AIS within guideline-directed treatment windows:

Dosing : 0.9 mg/kg IV (maximum total dose of 90 mg ).

Administration Architecture :

Initial 10% of the calculated dose administered as a rapid intravenous bolus over 1 minute .

Remaining 90% of the calculated dose administered as a continuous intravenous infusion over 60 minutes via an automated infusion pump.

Preparation & Line Flushing : Discard the excess volume from the vial prior to initiating the infusion to prevent accidental total overdose. At the conclusion of the 60-minute infusion, a 0.9% sodium chloride flush at the same infusion rate is mandatory to ensure all residual alteplase in the IV tubing is delivered to the patient.

Tenecteplase (TNK-tPA)

Tenecteplase is a genetically engineered variant of native tPA with three modifications: Thr103Asn, Asn117Gln, and replacement of the Lys-His-Arg-Arg sequence at positions 296–299 with four alanines. The TNKase label lists these advantages over native tPA:

80-fold greater resistance to inactivation by plasminogen activator inhibitor-1 (PAI-1).

14-fold greater fibrin specificity , resulting in enhanced thrombus targeting and reduced systemic depletion of circulating fibrinogen, alpha-2 antiplasmin, and clotting factors.

Prolonged terminal elimination half-life (~20 to 24 minutes vs. 4 to 5 minutes for alteplase), enabling delivery as a single rapid IV bolus .

AIS Dosing : 0.25 mg/kg IV single bolus (maximum dose of 25 mg ) administered over 5 to 10 seconds.

Clinical Trial Evidence: Alteplase vs. Tenecteplase

EXTEND-IA TNK (2018) : Evaluated AIS patients with large vessel occlusions (LVO) scheduled for endovascular thrombectomy (EVT). Patients receiving tenecteplase 0.25 mg/kg achieved significantly higher pre-thrombectomy reperfusion rates (22% vs. 10%, p=0.002) and superior 90-day functional recovery compared to alteplase.

AcT Trial (2022) : A large pragmatic Canadian registry trial (n=1,577) comparing tenecteplase 0.25 mg/kg against alteplase 0.9 mg/kg in all-comer AIS patients within 4.5 hours. Tenecteplase met non-inferiority criteria for the primary endpoint of 90-day modified Rankin Scale (mRS) 0 to 1 (36.9% vs. 34.8%), with identical rates of symptomatic intracranial hemorrhage (3.4% vs. 3.2%).

TIMELESS Trial (2024) : Tenecteplase 0.25 mg/kg given 4.5 to 24 hours after onset to patients with large vessel occlusion and salvageable penumbra, most of whom then had thrombectomy, did not improve 90-day functional outcome.

TRACE-III (2024) : In patients with large vessel occlusion 4.5 to 24 hours from onset who could not get thrombectomy, tenecteplase improved the chance of excellent functional outcome. This trial supports late-window thrombolysis where thrombectomy is unavailable.

Important

Regulatory and guideline status : the FDA approved tenecteplase (TNKase) for acute ischemic stroke in March 2025. The 2026 AHA/ASA guideline (Prabhakaran et al., Stroke , January 2026) recommends tenecteplase 0.25 mg/kg (maximum 25 mg) as an alternative to alteplase within 4.5 hours.

Tip

Operational efficiency is a major driver of tenecteplase adoption. Delivering a 5-second single bolus eliminates pump tubing management, accelerates door-to-needle time, and facilitates rapid "drip-and-ship" inter-facility transfer without infusion pump interruptions.

  • Time Windows and Strict Eligibility Criteria
  • Treatment Windows

Standard Window (0 to 3 hours) : Supported by the original NINDS rt-PA trial. Initiated within 3 hours from symptom onset or last known normal (LKN).

Expanded Window (3 to 4.5 hours) : Supported by the ECASS III trial, which excluded age over 80 years, NIHSS over 25, diabetes plus prior stroke, and oral anticoagulant use. Later AHA/ASA guidance no longer treats most of those trial exclusions as absolute in this window.

Extended Windows (2026 AHA/ASA guideline) : Thrombolysis may be reasonable for patients with salvageable ischemic penumbra on advanced imaging who wake up with symptoms (within 9 hours of the midpoint of sleep) or are 4.5 to 9 hours from last known well (EXTEND), and for patients with large vessel occlusion and salvageable tissue up to 24 hours when thrombectomy is not available (TRACE-III).

Non-disabling Deficits : For minor, non-disabling stroke within 4.5 hours, thrombolysis has not shown benefit, and dual antiplatelet therapy (aspirin plus clopidogrel) is preferred.

Absolute Exclusion Criteria for Intravenous Thrombolysis

Prior to administering alteplase or tenecteplase, the emergency medicine pharmacist must rigorously review absolute contraindications:

Acute Intracranial Hemorrhage : Confirmed on non-contrast head CT.

Recent Head Trauma or Stroke : Severe head trauma or ischemic stroke within the preceding 3 months .

Severe Uncontrolled Blood Pressure : Systolic blood pressure (SBP) ≥ 185 mmHg \ge 185\text{ mmHg} ≥ 185 mmHg or diastolic blood pressure (DBP) ≥ 110 mmHg \ge 110\text{ mmHg} ≥ 110 mmHg refractory to acute antihypertensive therapy.

Thrombocytopenia : Platelet count < 100 , 000 / μ L <100,000/\mu\text{L} < 100 , 000/ μ L .

Active Anticoagulant Use :

Warfarin with INR >1.7 or PT >15 seconds.

Unfractionated heparin within 48 hours resulting in an elevated aPTT >40 seconds .

Therapeutic Low Molecular Weight Heparin (LMWH, e.g., enoxaparin 1 mg/kg q12h) within 24 hours .

Direct Oral Anticoagulants (DOACs: apixaban, rivaroxaban, edoxaban, dabigatran) ingested within 48 hours , unless specific laboratory assays (calibrated anti-Xa level or diluted thrombin time) are undetectable, or > 48 >48 > 48 hours have elapsed with documented normal creatinine clearance.

Structural Intracranial Lesions : Intra-axial intracranial neoplasm is a contraindication. A small, unruptured, unsecured intracranial aneurysm (under 10 mm) or a benign extra-axial tumor such as a meningioma is not a reason to withhold treatment, and the 2026 guideline frames these as individualized decisions. The safety of thrombolysis with an unruptured arteriovenous malformation is uncertain, so it may be considered for severe deficits.

Active Internal Bleeding : Acute gastrointestinal malignancy or GI hemorrhage within the preceding 21 days .

Infective Endocarditis & Aortic Dissection : High risk of catastrophic secondary intracranial mycotic aneurysm rupture or hemorrhagic dissection propagation.

Blood Pressure Targets & Emergency Antihypertensive Protocols

Elevated blood pressure during acute ischemic stroke is often a compensatory physiological response to maintain cerebral perfusion through collateral vessels. However, excessive hypertension significantly elevates the risk of fatal hemorrhagic transformation when thrombolytics are administered.

Loading diagram...

Specific Hemodynamic Thresholds

Pre-Thrombolytic Threshold : SBP must be lowered to < 185 mmHg <185\text{ mmHg} < 185 mmHg and DBP to < 110 mmHg <110\text{ mmHg} < 110 mmHg BEFORE initiating alteplase or tenecteplase. If blood pressure cannot be maintained below 185/110 mmHg with first-line agents, thrombolytic therapy must be abandoned.

Post-Thrombolytic Maintenance : SBP must remain < 180 mmHg <180\text{ mmHg} < 180 mmHg and DBP < 105 mmHg <105\text{ mmHg} < 105 mmHg for at least the first 24 hours post-thrombolysis. The 2026 guideline adds that intensive lowering to an SBP below 140 mmHg after thrombolysis or thrombectomy is not recommended, because it does not improve outcomes and may harm after thrombectomy.

Monitoring Protocol : Check blood pressure every 15 minutes for 2 hours, then every 30 minutes for 6 hours, then every 60 minutes for 16 hours.

Permissive Hypertension : For AIS patients not receiving thrombolytics or EVT , blood pressure should not be treated acutely unless SBP > 220 mmHg >220\text{ mmHg} > 220 mmHg or DBP > 120 mmHg >120\text{ mmHg} > 120 mmHg or there is co-existing target end-organ damage (acute coronary syndrome, acute aortic dissection, hypertensive encephalopathy, or pulmonary edema). If treating, lower blood pressure conservatively by 15% within the first 24 hours.

First-Line Intravenous Antihypertensive Agents

Labetalol :

Mechanism : Combined competitive antagonist at alpha-1, beta-1, and beta-2 adrenergic receptors (7:1 beta-to-alpha blockade ratio intravenously).

Dosing : 10 to 20 mg IV push over 1 to 2 minutes; may repeat or double the dose every 10 to 20 minutes (up to a cumulative maximum of 300 mg), or initiate a continuous infusion at 2 to 8 mg/min.

Clinical Pearls : Avoid in severe bradycardia (HR <60 bpm), second- or third-degree heart block, and active acute decompensated heart failure.

Nicardipine :

Mechanism : Second-generation dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, producing potent peripheral and cerebral arterial vasodilation without negative inotropic or dromotropic effects.

Dosing : Initial continuous IV infusion at 5 mg/h ; titrate by 2.5 mg/h every 5 to 15 minutes to target blood pressure (maximum dose 15 mg/h ).

Clinical Pearls : Highly titratable with a predictable linear dose-response. Ensure infusion site rotation or large-vein access to minimize superficial phlebitis.

Clevidipine :

Mechanism : Third-generation ultra-short-acting dihydropyridine calcium channel blocker rapidly hydrolyzed by blood and tissue esterases (elimination half-life ~1 minute).

Dosing : Initial continuous IV infusion at 1 to 2 mg/h ; double the dose every 90 seconds until approaching target, then titrate by 2 to 4 mg/h every 5 to 10 minutes (maximum dose 32 mg/h ).

Clinical Pearls : Formulated in a 20% lipid emulsion (provides 2 kcal/mL; 0.2 g fat/mL). Strict aseptic technique required; discard vial and infusion line within 12 hours of puncture. Contraindicated in severe egg or soybean allergies and defective lipid metabolism (e.g., severe hypertriglyceridemia).

Warning

Avoid intravenous hydralazine as first-line therapy in acute stroke. Hydralazine exhibits an unpredictable, prolonged hypotensive response and triggers reflex sympathetic tachycardia. Avoid sodium nitroprusside except in refractory crisis due to risk of increased intracranial pressure and cerebral steal phenomenon.

Thrombolytic & Antihypertensive Reference Matrix

Pharmacologic Agent Mechanism / Class Standard ED Dosing Administration Pearls Critical Precautions & Pitfalls

Alteplase (rt-PA) Recombinant tPA 0.9 mg/kg IV (max 90 mg) 10% bolus over 1 min, 90% over 60 min Discard waste from vial prior to infusion. Flush line with saline after 60 min.

Tenecteplase (TNK) Genetically modified tPA 0.25 mg/kg IV single bolus (max 25 mg) Inject over 5 to 10 seconds Rapid reconstitution; no infusion pump required. Supported by AcT and EXTEND-IA TNK.

Nicardipine Dihydropyridine CCB 5 mg/h IV, titrate by 2.5 mg/h q5–15min Continuous infusion; max 15 mg/h First-line titratable agent; does not affect myocardial conduction or contractility.

Clevidipine Esterase-cleaved CCB 1 to 2 mg/h IV, double q90s Continuous infusion; max 32 mg/h Lipid vehicle (2 kcal/mL); change line q12h. Avoid in severe egg/soy allergies.

Labetalol Alpha-1 / Beta-blocker 10 to 20 mg IV push q10–20min May double to max 300 mg total Avoid in bradycardia, reactive airway bronchospasm, and decompensated heart failure.

  • Life-Threatening Post-Thrombolytic Complications
  • 1. Symptomatic Intracranial Hemorrhage (sICH)

Occurring in approximately 2% to 6% of patients, sICH is defined as new intracranial hemorrhage documented on neuroimaging associated with an acute neurological deterioration (drop in GCS or increase in NIHSS by ≥ 4 \ge 4 ≥ 4 points), acute severe headache, sudden vomiting, or acute secondary hypertension.

Immediate Reversal Protocol :

STOP the thrombolytic infusion immediately if still running.

Order an emergent non-contrast head CT and STAT neurosurgery consult.

Draw STAT laboratory tests: CBC, PT/INR, aPTT, fibrinogen, and type and crossmatch.

Cryoprecipitate : Administer 10 units IV bolus immediately. Cryoprecipitate is the primary source of concentrated fibrinogen, factor VIII, and von Willebrand factor. Recheck fibrinogen level at 1 hour post-infusion; if fibrinogen remains < 150 mg/dL <150\text{ mg/dL} < 150 mg/dL , administer an additional 10 units.

Antifibrinolytic Therapy : Administer Tranexamic Acid (TXA) 1000 mg IV infused over 10 minutes OR Aminocaproic acid 4 to 5 g IV over 1 hour followed by 1 g/h for 8 hours.

2. Orolingual Angioedema

Orolingual angioedema occurs in 1% to 5% of thrombolytic recipients. It is characterized by acute swelling of the tongue, lips, and oropharynx, often asymmetric. The risk is elevated 4- to 5-fold in patients taking ACE inhibitors due to impaired degradation of bradykinin, which is further amplified by plasmin-mediated activation of the contact kallikrein-kinin cascade.

Emergency Management Protocol :

Airway Protection : Maintain airway patency; prepare for immediate fiberoptic nasal or endotracheal intubation if stridor or laryngeal edema develops.

Discontinue Thrombolytic Infusion .

Corticosteroids & Antihistamines :

Methylprednisolone : 125 mg IV push.

Diphenhydramine : 50 mg IV push.

Famotidine : 20 mg IV push (H2 receptor blockade).

Epinephrine : For progressive airway compromise, administer epinephrine 0.3 mg IM (1:1,000 solution) into the anterolateral thigh or nebulized racemic epinephrine (0.5 mL of 2.25% solution).

Targeted Bradykinin Blockade : For refractory ACE-inhibitor-associated angioedema, administer Icatibant 30 mg subcutaneous injection (selective bradykinin B2 receptor antagonist) or Ecallantide 30 mg SC (plasma kallikrein inhibitor).